Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1645 1646 1671
This examiner grants 51% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18244849 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | Final Rejection | The Regents of the University of California |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | Non-Final OA | Genentech, Inc. |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | Final Rejection | GENENTECH, INC. |
| 18553042 | VACCINE COMPOSITION AGAINST CORONAVIRUS | Non-Final OA | LG CHEM, LTD. |
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18448644 | NEUTRALIZING ANTIBODY SPECIFIC TO HUMAN DENATURED CRP, AND MEDICINE AND ANTI-INFLAMMATORY AGENT CONTAINING THE SAME | Non-Final OA | CANON MEDICAL SYSTEMS CORPORATION |
| 18547748 | METHODS FOR TREATING CD83-EXPRESSING CANCER | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17786917 | METHODS FOR TREATING GLIOBLASTOMA | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 16859252 | SHARED NEOANTIGENS | Final Rejection | The General Hospital Corporation |
| 18022593 | Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same | Non-Final OA | The University Of Tokyo |
| 17910544 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Final Rejection | TORAY INDUSTRIES, INC. |
| 17535492 | METHODS OF TREATING UROTHELIAL CARCINOMA | Non-Final OA | Foundation Medicine, Inc. |
| 17642566 | COMBINATIONS AND METHODS FOR TREATING CANCER | Non-Final OA | University of South Florida |
| 18837546 | STABLE PLINABULIN FORMULATIONS AND METHODS OF THEIR PREPARATION AND USE | Non-Final OA | BeyondSpring Pharmaceuticals, Inc. |
| 17923189 | TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY | Non-Final OA | BeyondSpring Pharmaceuticals, Inc. |
| 18848994 | COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC THERAPY | Non-Final OA | BODHI BIO LLC |
| 18337693 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT | Final Rejection | Boehringer Ingelheim International GmbH |
| 17693918 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS | Non-Final OA | Meso Scale Technologies, LLC. |
| 17667714 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS | Final Rejection | Meso Scale Technologies, LLC. |
| 16971992 | TISSUE ANALYSIS BY MASS SPECTROMETRY | Non-Final OA | BAYLOR COLLEGE OF MEDICINE |
| 17946094 | METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODY | Non-Final OA | The United States GOVERNMENT As represented By The Department of Veterans Affairs |
| 17817735 | CHIMERIC ANTIGEN RECEPTORS WITH CD28 MUTATIONS AND USE THEREOF | Non-Final OA | Memorial Sloan-Kettering Cancer Center |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | Non-Final OA | Merus N.V. |
| 18499104 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | Non-Final OA | Immix Biopharma, Inc |
| 17895936 | METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS | Non-Final OA | Ventana Medical Systems, Inc. |
| 18550438 | STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | OPSIDIO, LLC |
| 18252759 | USES OF EFFECTOR CELL ENGAGING MOLECULES WITH MOIETIES OF DIFFERING POTENCIES | Non-Final OA | IGM Biosciences, Inc. |
| 18458997 | HER3 ANTIGEN-BINDING MOLECULES | Non-Final OA | Hummingbird Bioscience Pte. Ltd. |
| 18262872 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | Non-Final OA | Vir Biotechnology, Inc. |
| 17632110 | METHOD FOR DIRECTLY DETECTING PATHOGENIC STRAIN HAVING RESISTANCE TO BETA-LACTAM ANTIBIOTICS | Non-Final OA | SEEGENE MEDICAL FOUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy